Genetic Technologies Limited
GENE
$0.765
-$0.015-1.92%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.03M | 5.32M | 5.65M | 5.72M | 5.85M |
| Total Other Revenue | 1.32M | 1.24M | 1.16M | 1.14M | 1.12M |
| Total Revenue | 6.34M | 6.56M | 6.81M | 6.86M | 6.97M |
| Cost of Revenue | 2.47M | 2.54M | 2.63M | 2.76M | 2.92M |
| Gross Profit | 3.88M | 4.02M | 4.19M | 4.10M | 4.05M |
| SG&A Expenses | 7.67M | 7.48M | 7.33M | 7.27M | 7.27M |
| Depreciation & Amortization | 350.80K | 382.70K | 417.50K | 434.60K | 455.60K |
| Other Operating Expenses | 2.31M | 2.38M | 2.46M | 2.46M | 2.47M |
| Total Operating Expenses | 13.29M | 13.39M | 13.58M | 13.72M | 13.98M |
| Operating Income | -6.95M | -6.84M | -6.77M | -6.86M | -7.01M |
| Income Before Tax | -7.88M | -8.14M | -8.45M | -8.20M | -8.02M |
| Income Tax Expenses | -- | -3.40K | -6.90K | -55.60K | -106.20K |
| Earnings from Continuing Operations | -7.88 | -8.14 | -8.44 | -8.15 | -7.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.88M | -8.14M | -8.44M | -8.15M | -7.91M |
| EBIT | -6.95M | -6.84M | -6.77M | -6.86M | -7.01M |
| EBITDA | -6.60M | -6.55M | -6.55M | -6.62M | -6.76M |
| EPS Basic | -0.06 | -0.07 | -0.07 | -0.08 | -0.08 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.08 | -0.08 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 528.87M | 490.27M | 451.68M | 428.60M | 405.52M |
| Average Diluted Shares Outstanding | 528.87M | 490.27M | 451.68M | 428.60M | 405.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
